Repotrectinib Overcomes F2004V Resistance Mutation in
Case report
Entrectinib
ROS1 F2004V
Repotrectinib
Resistance
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
22
05
2023
revised:
14
07
2023
accepted:
17
07
2023
medline:
4
12
2023
pubmed:
4
12
2023
entrez:
4
12
2023
Statut:
epublish
Résumé
ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds are under clinical development. ROS1 F2004 substitutions have been previously detected on circulating tumor DNA of patients progressing to entrectinib. Hereby, we report the case of a patient with ROS1+ NSCLC in which F2004V-acquired mutation was detected on a site of disease progression, after entrectinib and crizotinib failure. A subsequent treatment with next-generation TKI repotrectinib led to disease response, providing the first clinical evidence of activity of repotrectinib against F2004V resistance mutation.
Identifiants
pubmed: 38047274
doi: 10.1016/j.jtocrr.2023.100555
pii: S2666-3643(23)00098-X
pmc: PMC10689265
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100555Informations de copyright
© 2023 The Authors.
Références
JCO Precis Oncol. 2017;2017:
pubmed: 29333528
JCO Precis Oncol. 2019 Jun 3;3:
pubmed: 32914039
Pulmonology. 2022 Jan-Feb;28(1):76-79
pubmed: 34627770
Mol Cancer Ther. 2022 Feb;21(2):336-346
pubmed: 34907086